- Conditions
- Head and Neck Cancer, Skin Cancer
- Interventions
- Questionnaire
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 817–840
of 1,581
matching trials from the live ClinicalTrials.gov search.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Interventions
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Biological
- Lead sponsor
- Atara Biotherapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphoma
- Interventions
- recombinant interferon alfa, bexarotene
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 5
- States / cities
- Miami, Florida • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory
- Interventions
- Mogamulizumab
- Drug
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 7
- States / cities
- Duarte, California • Irvine, California • Stanford, California + 4 more
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- American ginseng, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 326
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 208 more
- Conditions
- Breast Cancer, Surgery
- Interventions
- IONM procedure
- Procedure
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Healthy
- Interventions
- Estradiol Transdermal System Placebo - Alternate Adhesive, Estradiol Transdermal System Placebo - Current Adhesive
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 40 Years to 66 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Cutaneous Melanoma, Mucosal Melanoma
- Interventions
- Nemvaleukin Alfa Subcutaneous, Nemvaleukin Alfa Intravenous, Nemvaleukin Alfa Intravenous Less Frequent Dosing, Pembrolizumab
- Drug
- Lead sponsor
- Mural Oncology, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • Jacksonville, Florida + 5 more
- Conditions
- T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Interventions
- Optional Blood Sample and Nail Sample
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 26
- States / cities
- Duarte, California • San Diego, California • San Francisco, California + 20 more
- Conditions
- Operative Wound
- Interventions
- Everted closure, Planar closure
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Cutaneous Angiosarcoma
- Interventions
- Ivonescimab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Head Lice
- Interventions
- Abametapir Lotion 0.74% w/w, Sodium Lauryl Sulfate, Saline 0.9%, Placebo
- Drug
- Lead sponsor
- Dr. Reddy's Laboratories Limited, India
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Paramus, New Jersey
- Conditions
- Rotator Cuff Tears, Rotator Cuff Injuries
- Interventions
- Arthroscopic rotator cuff repair; Biological: Dermis on Demand, Arthroscopic rotator cuff repair
- Procedure
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- busulfan, cyclophosphamide, cytarabine, allogeneic bone marrow transplantation
- Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma, Lentigo Maligna Melanoma, Low-CSD Melanoma, Mucosal Melanoma, Recurrent Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Dinaciclib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2027
- U.S. locations
- 190
- States / cities
- Mobile, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 126 more
- Conditions
- Migraine
- Interventions
- Migranal nasal spray at 1 hour, Migranal nasal spray at 4 hour
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- MTX-474, Placebo
- Biological · Other
- Lead sponsor
- Mediar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • La Jolla, California • Loma Linda, California + 19 more
- Conditions
- Pigmented Skin Lesion
- Interventions
- Dermal Cooling System
- Device
- Lead sponsor
- R2 Dermatology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 377 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Walnut Creek, California
- Conditions
- Total Knee Replacement, Genicular Nerve Block, Opioid Use
- Interventions
- Bupivacaine Injection, Dexamethasone injection, Fentanyl, Mepivacaine
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Sézary Syndrome
- Interventions
- Naloxone Hydrochloride Lotion, 0.5%, Placebo Lotion
- Drug
- Lead sponsor
- Elorac, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 16
- States / cities
- Little Rock, Arkansas • Duarte, California • Palo Alto, California + 11 more
- Conditions
- Advanced Melanoma
- Interventions
- Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice
- Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 19 more
- Conditions
- Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Pembrolizumab
- Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 8
- States / cities
- Palo Alto, California • New Haven, Connecticut • Tampa, Florida + 5 more
- Conditions
- Cutaneous Lupus Erythematosus
- Interventions
- laser treatment (Candela Vbeam Perfecta™)
- Procedure
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Pure Autonomic Failure
- Interventions
- Skin Biopsy
- Diagnostic Test
- Lead sponsor
- CND Life Sciences
- Other
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 428 participants
- Timeline
- 2021 – 2023
- U.S. locations
- 23
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 19 more